HC Wainwright Reiterates “Buy” Rating for GH Research (NASDAQ:GHRS)

GH Research (NASDAQ:GHRS)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report released on Thursday, Benzinga reports. They presently have a $40.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 386.03% from the company’s current price.

Separately, JMP Securities reiterated a “market outperform” rating and set a $39.00 price objective on shares of GH Research in a research note on Wednesday.

GH Research Stock Performance

GHRS stock opened at $8.23 on Thursday. The company’s 50-day simple moving average is $11.11 and its 200 day simple moving average is $11.17. GH Research has a 52 week low of $5.05 and a 52 week high of $14.99. The company has a market capitalization of $428.19 million, a PE ratio of -13.27 and a beta of 0.83.

GH Research (NASDAQ:GHRS) last released its quarterly earnings results on Tuesday, September 3rd. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.03. On average, analysts forecast that GH Research will post -0.84 EPS for the current year.

Institutional Investors Weigh In On GH Research

A number of large investors have recently bought and sold shares of the company. AdvisorShares Investments LLC lifted its holdings in shares of GH Research by 4.3% in the fourth quarter. AdvisorShares Investments LLC now owns 48,300 shares of the company’s stock worth $280,000 after acquiring an additional 1,977 shares during the last quarter. Lynx1 Capital Management LP lifted its holdings in shares of GH Research by 80.1% in the first quarter. Lynx1 Capital Management LP now owns 3,310,563 shares of the company’s stock worth $35,291,000 after acquiring an additional 1,471,946 shares during the last quarter. BVF Inc. IL lifted its holdings in shares of GH Research by 12.1% in the fourth quarter. BVF Inc. IL now owns 10,400,158 shares of the company’s stock worth $60,321,000 after acquiring an additional 1,125,000 shares during the last quarter. Finally, RA Capital Management L.P. lifted its holdings in shares of GH Research by 11.9% in the first quarter. RA Capital Management L.P. now owns 6,251,714 shares of the company’s stock worth $66,643,000 after acquiring an additional 664,381 shares during the last quarter. 56.90% of the stock is currently owned by institutional investors and hedge funds.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).